Nigel Greig, PhD, Drug Design & Development Section, Intramural Research
Program, National Institute on Aging, NIH. Nigel Greig is the inventor of QR
Pharma's compounds. He has been officially approved by the NIH Ethics Committee and by the NIA/NIH Executive Board to work with QR Pharma and chair the SAB. Dr. Greig was the inventor of the technology that led to the founding of Athena Neuroscience.
National Institute on Aging
More
Don Ingram, PhD, Pennington Biomedical Research Center, LSU, Baton Rouge, LA
Dr. Ingram joined the Pennington Biomedical Research Center in 2006 as Professor in the Nutritional Neuroscience and Aging Laboratory after he retired from the National Institute on Aging, National Institutes of Health, where he served since 1980, most recently as Chief of the Laboratory of Experimental Gerontology. He received his B.A. in psychology from Louisiana State University in 1970 and his doctorate in psychology and gerontology from the University of Georgia in 1978 followed in 1979 by a Postdoctoral Fellowship at the Jackson Laboratory, Maine.
His research focuses on pharmacological interventions designed to attenuate aging, age-related disease, and functional decline. His research has produced patented drugs for treating Alzheimer’s disease
Dr. Ingram serves on editorial boards of several biomedical journals, and is Editor-in-Chief of AGE. He has also served in numerous official positions within the Gerontological Society of America, and he is a past president of the American Aging Association and the 2003 recipient of their Harman Research Award. Dr. Ingram has authored over 325 scientific publications, including journal papers, reports, and chapters and serves as consultant for several companies.
Debomoy Lahiri, PhD, Psychiatry Dept., Indiana University School of Medicine, Indianapolis, IN
Dr.Lahiri is Professor in the Department of Psychiatry and of Medical & Molecular Genetics and full member of the Stark Neurosciences Research Institute at the Indiana University (IU) School of Medicine, Indianapolis. Currently, he is Chief of the Laboratory of Molecular Neurogenetics and Associate Director of INBRAIN (Indiana Center for Biomarker Research in Neuropsychiatry) at the Institute of Psychiatric Research of IU School of Medicine. Prior to joining Indiana University, Dr. Lahiri was a faculty member at Mount Sinai School of Medicine, New York, NY.
His particular research interest is in understanding the mechanism of aging; origin and biogenesis of the amyloid plaque and gene regulation of Alzheimer's disease (AD). Dr. Lahiri has been awarded multiple research grants as a Principal Investigator from the National Institute on Aging, National Institutes of Health (NIH) and Alzheimer's Association. Dr. Lahiri is a current member of the NIH study section, of the Scientific Advisory Board for the Institute for the Study of Aging, New York and a consultant to Forest Research Labs, NY. He has published over 200 scientific papers in the field of neurobiology, genetics and AD (including high impact factor journals, such as JBC, PNAS, FASEB J, JPET, and Nature Neurosci Rev).
Dr. Lahiri is the Editor-In-Chief of the international journal, ‘Current Alzheimer Research', which is listed in MEDLINE/PubMed (www.bentham.org). He has also edited books, such as ‘Protective Strategies for Neurodegenerative Diseases' published by the New York Academy of Sciences. Dr. Lahiri's honors include the listing in Marquis' ‘Who's Who in the World', and receiving the prestigious ‘Zenith Award' from Alzheimer's Association.
Kumar Sambamurti, PH.D. Department of Neuroscience, Medical University of South Carolina, SC
The Sambamurti laboratory has a long-standing interest in understanding the biochemical basis of Alzheimer disease and its relationship to other neurodegenerative diseases. The laboratory has proposed a hypothesis that failure of membrane protein turnover (including APP) is the triggering event in Alzheimer disease pathogenesis. Thus, rather than viewing the amyloid peptide as a unique target for reduction, the lab focuses on facilitation of the turnover pathways for APP and other membrane proteins. Posiphen® constitutes a novel category of agents that aim to reduce the synthesis of APP, thereby reducing the load of this protein on its turnover pathways. The hypothesis extends to other degenerative diseases, including age-related macular degeneration and glaucoma.
Dr. Sambamurti did his BSc from Madras University and MSc from Pune University, India and subsequently completed his Ph.D. at the University of Medicine and Dentistry (UMD) of New Jersey in 1989. He subsequently did a post-doctoral fellowship with Dr. Nikolaos Robakis at the Mount Sinai Medical Center where he stated his research on the proteolytic processing of A PP. He then went to the University of Texas Houston and the Mayo Clinic-Jacksonville as an Assistant Professor. He Joined the Medical University of South Carolina where he progressed to become a tenured Research Professor in 2008. Dr. Sambamurti is also the Co-Director of the Carol Campbell brain bank.
MUSC Profile